CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

Pfizer says it will appeal the Aug 1 ruling to Britain’s Supreme Court. Read more at straitstimes.com. Read more at ...

A U.K. Court of Appeals ruling confirms the validity of a patent covering modifications of mRNA used in Moderna’s vaccines.

BioNTech stock was rising after the drugmaker reported better-than-expected results early Monday. The company’s ...

Pfizer beats Q2 2025 estimates, raises EPS guidance, boasts a 7%+ dividend yield, yet faces patent and pricing risks. See why ...

BioNTech reiterated its guidance for 2025 revenues of 1.7 billion to 2.2 billion euros, down from 2.75 billion last year.

The company expects that the U.S. COVID-19 vaccination rate will be “maybe a couple of points lower” than the prior level of ...

PFE posts strong Q2 results with earnings up 30% and revenues up 10% year over year, fueled by rising oncology sales and cost ...

BioNTech's COVID-19 vaccine on one's eye, which could lead an indivual to permanent vision loss. Read on... TheHealthSite.com ...

London's Court of Appeal on Friday struck down a case filed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX), in a bid to ...